Drug Profile
Research programme: antiviral therapeutics - Galapagos
Latest Information Update: 28 Mar 2019
Price :
$50
*
At a glance
- Originator Galapagos NV
- Developer Galapagos NV; Rega Institute for Medical Research; University Hospital Heidelberg
- Class
- Mechanism of Action Viral protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for research development in Hepatitis-B in Belgium
- 12 Feb 2015 Early research in Hepatitis B in Belgium (unspecified route)